# Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

> **NCT03403374** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 30 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia HoFH

## Interventions

- **DRUG:** evolocumab

## Key facts

- **NCT ID:** NCT03403374
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-04
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403374, "Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03403374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*